Didactic Presenter:

 Raphael E. Szalat, MD, PhD
 Assistant Professor of Medicine
 Director, Multiple Myeloma Program
 Director, Stem Cell Transplant Program
 Section of Hematology and Medical Oncology
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, MA

Raphael E. Szalat, MD, PhD received his medical training at the University of Pierre and Marie Curie in Paris, France. After internal medicine residency, Szalat specialized in immunology and plasma cell disorders, including multiple myeloma and monoclonal gammopathies of clinical significance, and became a clinical assistant professor in the Department of Immuno-Hematology in Saint-Louis Hospital, Paris. He next completed a PhD and postdoc in hematology, studying genomics in multiple myeloma at the Dana-Farber Cancer Institute, Harvard Medical School, in collaboration with La Sorbonne University, Paris, and a clinical fellowship in hematology and oncology at the Boston University Medical Center.

Dr. Szalat currently serves as director of the Multiple Myeloma Program and the Stem Cell Transplant Program at the Boston University Medical Center. His main interests are developing myeloma clinical trials and performing basic and translational research on multiple myeloma and other plasma cell disorders, including AL amyloidosis and other monoclonal gammopathies of clinical significance.

Dr. Raphael Szalat, program Co-Chair, is a consultant for Johnson & Johnson.

Disclosure Policy:
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.